Alliances

Found 54,227 articles

• LABCORP AND JEFFERSON HEALTH ANNOUNCE STRATEGIC LABORATORY RELATIONSHIP

  5/3/2023

  Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia area and Southern New Jersey.

• Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications

  5/3/2023

  Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells.

• American Lung Association, Gateway for Cancer Research Partner to Develop Personalized Lung Cancer Vaccine

  5/3/2023

  Gateway for Cancer Research, a nonprofit organization dedicated to funding transformational early phase cancer clinical trials around the world, today announced a new partnership with the American Lung Association Research Institute.

• Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health

  5/2/2023

  Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies.

• Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies

  5/2/2023

  Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.

• Cellular Biomedicine Group Announces Exclusive Collaboration and License Agreement with Janssen to Develop and Commercialize anti CD19 & CD20 Bi-Specific and anti CD20 CAR-Ts for Non-Hodgkin Lymphoma

  5/2/2023

  Cellular Biomedicine Group Inc. (CBMG or the Company), a clinical-stage biopharmaceutical company focused on discovery and development of innovative cellular therapies for cancer and autoimmune diseases, today announced that the Company has entered into a global collaboration and license agreement with Janssen Biotech, Inc.

• Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

  5/2/2023

  Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an agreement with IMP Clinical Supply Services (“IMP”).

• Curasight and Curium announce global partnership for uTRACE® in prostate cancer

  5/2/2023

  Curasight A/S announced that it has entered into an exclusive global license and collaboration agreement with Curium Inc. – a global leader in radiopharmaceuticals – for the development and commercialization of uTRACE® for use in prostate cancer.

• Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited

  5/1/2023

  Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that its wholly owned subsidiary Aptorum Therapeutics Limited (“ATL”) has entered into a non-binding Letter of Intent and Term Sheet (“Term Sheet”) to merge (“Transaction”) its 100% subsidiary, Paths Innovation Limited.

• EarlySign Expands Collaboration with Roche in Supporting the Early Detection of Colon Cancer

  5/1/2023

  Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical predictive analytics, announced at the recent HIMSS Conference a new agreement with Roche, which will allow for EarlySign ColonFlag to be offered within the navify® Algorithm Suite from Roche Diagnostics.

• Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

  5/1/2023

  Marker Therapeutics, Inc. today announced that it has entered into a comprehensive agreement with CellReady™, a newly formed Contract Development and Manufacturing Organization (CDMO) founded by John Wilson, founder and CEO of Wilson Wolf Corporation and Marker Co-Founder and Board Member.

• Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease

  5/1/2023

  Soligenix, Inc. today announced that it has entered into an exclusive option agreement with Silk Road Therapeutics, a privately-held company.

• Flatiron Health Embarks on Strategic Collaboration with Sanofi to Make Clinical Trials More Efficient by Streamlining Data Acquisition at the Point of Care

  5/1/2023

  Flatiron Health announced a new collaboration today with Sanofi in their pursuit to redesign the clinical trial experience for sponsors, sites, and patients in the therapeutic area of oncology.

• 2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program

  5/1/2023

  2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program.

• Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

  5/1/2023

  Immatics N.V. (NASDAQ: IMTX, “Immatics”) today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option and entered into an exclusive worldwide license for the first T cell receptor engineered T cell therapy (TCR-T) candidate from their ongoing collaboration.

• Lannett Company, Inc. Enters Into Restructuring Support Agreement

  5/1/2023

   Lannett Company, Inc. (OTCMKTS: LCIN) (the "Company" or "Lannett") today announced that, together with certain of its subsidiaries (collectively with the Company, as applicable, the "Company Parties"), it has entered into a Restructuring Support Agreement (the "RSA") with holders of more than 80% of its 7.750% senior secured notes due 2026.

• Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

  5/1/2023

  Ovid Therapeutics Inc. and Graviton Bioscience Corporation announced a collaboration agreement to innovate novel medicines that they believe will significantly change the treatment paradigm for serious, rare neurological diseases.

• Nuvo Group Ltd., A Leading FDA-Cleared Innovator in Pregnancy Care, and LAMF Global Ventures Corp I, Led by Chairman Jeffrey Soros and CEO Simon Horsman, Announce Intent to List Nuvo on Nasdaq Through a Business Combination

  4/28/2023

  LAMF Global Ventures Corp I announced today that they have entered into a non-binding letter of intent (the “LOI”) for a proposed business combination.

• Gene Bio Medical Announces Partnership with Prairie Hub for Pandemic Preparedness

  4/28/2023

  Gene Biotechnology Enterprises Ltd, doing business as Gene Bio Medical, is proud to announce its partnership with the Prairie Hub for Pandemic Preparedness as a key commercialization partner.

• Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development

  4/27/2023

  Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company.